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Abstract
Objective: The coincidence of chronic pancreatitis and liver cirrhosis in alcoholic patients is comparatively rare.
Our aim was to assess liver fibrosis in patients with alcoholic chronic pancreatitis (ACP) by measuring noninvasive
fibrosis scores and liver stiffness.
Methods: Fifty-five patients with ACP were enrolled in the study. Eight healthy volunteers served as controls.
Noninvasive fibrosis scoring systems, including the aspartate aminotransferase to platelet ratio index (APRI) and
fibrosis-4 score (FIB-4), were determined and transient elastography (TE) was performed.
Results: Mild (F1 or F2) and severe (F3 or F4) fibrosis was revealed by TE in 15 and 6 patients (38.2%),
respectively. However, the levels of the liver enzymes were elevated in only 12 patients. The APRI and FIB-4 scores
jointly revealed fibrosis of the liver in two patient. ACP patients with liver fibrosis drank significantly more amount of
alcohol and had diabetes more frequently than ACP patients without liver fibrosis.
Conclusion: Liver fibrosis was revealed by TE in one-fourth of the ACP patients. Liver enzymes are not reliable
parameters with which to diagnose liver fibrosis. The quantity of consumed alcohol and the presence of DM are risk
factors for the development of liver fibrosis in ACP.
Keywords: Chronic pancreatitis; Liver fibrosis; Diabetes mellitus;
Transient elastography; Liver enzymes
Abbreviations: ACP: Alcoholic Chronic Pancreatitis; ALC:
Alcoholic Liver Cirrhosis; APRI: Aspartate Aminotransferase to
Platelet Ratio Index; CP: Chronic Pancreatitis; CT: Computed
Tomography; DM: Diabetes Mellitus; ERCP: Endoscopic Retrograde
Cholangiopancreatography; FIB-4: Fibrosis-4 Score; MRCP: Magnetic
Resonance Cholangiopancreatography; TE: Transient Elastography;
US: Abdominal Ultrasonography.
Introduction
Although chronic ethanol consumption is a common etiological
factor, the coincidence of chronic pancreatitis (CP) and liver cirrhosis
in alcoholic patients is relatively rare [1,2]. Different morphological
and functional examinations have revealed the presence of alcoholic
liver fibrosis (ALF) in only 10-20% of alcoholic CP (ACP) patients
[3-6]. The rare coincidence of clinical and morphological alterations in
ALF and ACP, and an inverse correlation between the indices of the
pancreatic and liver functions evaluated by the fecal elastase-1 test and
the indocyanine green test have been described [7]. These results
support the hypothesis of the independent pathogenesis of ALF and
ACP and suggest the presence of another etiological factor such as a
genetic predisposition [8].
It may be assumed that the sociobehavioral factors of ACP and ALF
also differ. ACP has been found to be more common in patients who
smoke, have a long-term history of alcohol consumption, and prefer to
drink spirits, and have a relatively low level of education [9], whereas
ALF was reported to be more frequent in smokers [1]. The duration of
chronic alcohol abuse proved to be shorter in ACP than in ALF, and
cirrhosis was more characteristic among older subjects [3,10].
According to Gullo et al. the duration of alcohol consumption was
significantly longer in ACP patients with ALF than in ACP patients
without ALF [11].
Although liver biopsy is currently the gold standard for the
diagnosis of liver cirrhosis, it has many drawbacks, such as the
sampling error, the cost, and the risk of complications [12-14].
Noninvasive markers are increasingly used for the assessment of liver
fibrosis, such as serum biomarkers and transient elastography (TE). TE
was originally developed to measure the stage of liver fibrosis by
assessing the stiffness of the liver in a noninvasive manner through the
use of ultrasonography in cases of chronic hepatitis C infection
[15-19]. TE has been demonstrated to be a suitable method to reveal
the severity of liver fibrosis in CP and concomitant cholestasis through
measurement of the liver stiffness [6]. It is also useful to predict
outcome in portal hypertension, variceal bleeding, hepatocellular
carcinoma and postoperative patients [20-22].
The aim of the present study was to assess the liver fibrosis in
patients with CP by measuring noninvasive fibrosis scores and liver
stiffness by means of TE.
Patients and Methods
Patients with ACP were enrolled in the study and volunteers were
recruited to serve as controls. CP was diagnosed on the basis of
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morphological diagnostic criteria [23,24]. Abdominal ultrasonography
(US) and computed tomography (CT) were performed in all patients.
Magnetic resonance cholangiopancreatography (MRCP) and/or
endoscopic ultrasound was performed when CT was equivocal. Fecal
elastase-1 test was performed to diagnose exocrine pancreatic function
in some patients. Patients with cystic fibrosis and other etiologies of
CP, cholestasis and viral, metabolic and autoimmune liver diseases
were excluded from the study.
Noninvasive fibrosis scores including the aspartate aminotransferase
to platelet ratio index (APRI) [25] and fibrosis-4 score (FIB-4) [26]
were determined.
TE was performed with a Fibroscan 402 (Echosens, Paris, France)
device. Measurements were made from one to three measuring points;
the success rate was 78-100% with an average of 21 (10-42) valid shots
per patient, expressed in kilopascals (kPa). The European Association
for the Study of Liver (EASL) Clinical Practice Guideline was used to
evaluate the measured values [27]. Fibrosis was staged by the Metavir
scoring system [28-31] and TE results were compared with the
noninvasive fibrosis scoring parameters.
All participants provided their written informed consent. The study
protocol was in full accordance with the most recent revisions of the
Helsinki Declaration and was approved by the ethics committee at the
University of Szeged. SPSS 22.0 (Armonk, New York, USA) was used
for the two samples t-test and chi-square test. P<0.05 was considered
statistically significant.
Results
Fifty five consecutive patients (39 males and 18 females, mean age
61.85 ± 9.85 years, mean BMI 23.83 ± 4.4 kg/m2) with ACP and 8
healthy volunteers (4 males and 4 females, mean age 53 ± 10 years,
mean BMI 22.1 ± 3 kg/m2) as controls were enrolled in the study. All
the ACP patients previously had regularly consumed alcohol, but only
12 (21.8%) were still active drinkers at the enrolment. 77% of the
patients were additionally smokers, and 35 (63.6%) were active
smokers at the enrolment. The TE values of the ACP patients were
significant higher than those of the controls (6.13 ± 2.99 /3.2-18.5/ vs.
4.7 ± 0.7 /3.9-5.5/ kPa, p=0.0029). Mild (F1 or F2) or severe (F3 or F4)
fibrosis was revealed by TE in 15 and 6 patients, respectively. However,
the liver enzymes were elevated in only 12 patients, 4 of them active
drinkers, 6 in F0, 1 in F2, 3 in F3 and 2 in F4 metavir stages. The APRI
and FIB-4 scores jointly revealed fibrosis of the liver in only 2 patient
(Table 1).
The clinical characteristics of ACP patients with and without liver
fibrosis were compared (Table 2). ACP patients with liver fibrosis
drank significantly more amount of alcohol and had diabetes more
frequently than ACP patients without liver fibrosis.
  Cases Controls
Successful transient
elastography  55 8
Metavir stages F0 34 8
 F1 or F2 15 0
 F3 or F4 6 0
Elevated levels of liver
enzymes F0 6 0
 F1 or F2 1 0
 F3 or F4 5 0
APRI ≤ 0.7 53 8
 (no fibrosis)   
 0.71-1.0 0 0
 (hepatic fibrosis)   
 <1.0 2 0
 (hepatic cirrhosis)   
FIB-4 score <1.45 27 7
 
(no advanced hepatic
fibrosis)   
 1.45-3.25 22 1
 (indeterminate score)   
 <3.25 6 0
 
(advanced hepatic
fibrosis)   
Table 1: Transient elastography, liver enzymes and noninvasive fibrosis
scoring results on patients with alcoholic chronic pancreatitis.
ACP with liver
fibrosis
ACP without
liver fibrosis
p
values
No. of cases (%) 21/55 (38.2%) 34/55 (61.8%) –
Male/female 13-Aug 26-Aug
Mean age (years) 62.71 (46-78) 61.32 (37-83) 0.59
Mean weight (kg) 67.62 (41-105) 71.59 (43-90) 0.363
Duration of ACP (years) 11.57 ± 5.17 9.79 ± 5.31 0.227
Active alcohol consumers
(%) 28.57 17.65 0.228
Duration of alcohol abuse
(years) 13.95 ± 4.28 11.76 ± 4.66 0.082
Mean amount of alcohol
intake (unit/week) 63.57 ± 19.5 52.21 ± 18.35 0.038
Active smokers (%) 66.66 61.76 0.314
Presence of diabetes
mellitus (%) 52.38 32.35 0.012
Duration of diabetes
mellitus (years) 8.54 ± 4.45 8.78 ± 5.84 0.454
HgbA1c (%) 7.2 (5.1-10.6) 6.5 (4.8-8.3) 0.072
Pancreatic surgery (%) 38.09 35.29 0.336
Calcification of the
pancreas (%) 61.9 50 0.528
Table 2: Clinical characteristics of alcoholic chronic pancreatitis
patients.
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Discussion
Although the main etiological factor of ACP and ALF is common,
the association of the two diseases is rather low. Previous studies with
the following methods described the presence of liver fibrosis in
10-20% of patients with ACP: ERCP and secretin-cerulein test (12.5%)
[3], liver biopsy (13.3%) [4], autopsy (20%) [5] and TE (10-15%) [6].
TE is a diagnostic modality that can assess the extent of liver
fibrosis. The method has been evaluated extensively in patients with
chronic hepatitis C infection [15-19]. It was recently demonstrated,
that the degree of liver stiffness measured by TE in CP patients with
concomitant cholestasis was correlated with the histologically
indicated stage of liver fibrosis [6].
The aim of the current prospective study was to assess the
occurrence of liver fibrosis in patients with CP by measuring
noninvasive fibrosis scores and liver stiffness with TE. CP patients,
diagnosed by imaging modalities, such as CT, MRCP, EUS were
enrolled. CT has a good accuracy revealing the characteristic
morphological alterations (calcification, pancreatic duct dilatation,
pancreatic atrophy) in our patients with advanced CP.
The etiology of the pancreatitis was alcohol abuse in all patients.
Among the noninvasive fibrosis scores, the levels of liver enzymes were
elevated in 12 patients and the APRI and FIB-4 score were both
normal except in six case. However, TE identified liver fibrosis in 21
(38.2%) of the ACP patients. These results suggest that the levels of the
liver enzymes and the noninvasive fibrosis scores are not reliable
parameters with which to reveal liver fibrosis in ACP. The effectiveness
of the use of these noninvasive scores was earlier demonstrated to be
lower than that of TE in diagnosing liver cirrhosis [6]. Furthermore,
liver fibrosis in ACP patients was diagnosed by TE more frequently in
our study than published earlier. This could be explained that patients
in our study had long standing, advanced ACP with calcification,
endocrine insufficiency and pancreatic surgery.
We compared the characteristics of the ACP patients with or
without TE-diagnosed liver fibrosis. The amount of alcohol
consumption was higher and DM due to FCP (type III/c diabetes) was
significantly more frequent in ACP patients with liver fibrosis than in
those without liver fibrosis. These results may suggest that the toxic
injury was more severe and prolonged and the severity of ACP was
more advanced in the ACP patients with liver fibrosis group [32,33].
Moreover, DM may induce steatohepatitis, which may act synergistic
ally with alcohol to result in the liver parenchyma alterations and the
TE findings [34,35]. DM was more frequent in our ACP patients than
in a previous study [6] and this may explain the higher rate of ALF in
our study as compared to the previous results.
The two major causes of chronic liver disease in patients with ACP
are alcohol abuse and/or compression of the biliary duct [1,3,9-11,36].
Cholestasis due to the fibrous pancreatic head was an exclusion
criterion in our study, and therefore only the toxic etiology of the liver
injury was assessed.
The drawbacks of our study include the low number of recruited
patients and the fact that liver fibrosis indicated by TE was not always
confirmed by histological examination. Liver biopsy is regarded as the
gold standard for the assessment of the presence of liver fibrosis, but
this technique is associated with a significant rate of complications
[37].
The use of TE may be of particular interest in ACP patients because
an abnormal finding is strongly suggestive of a fibrogenic process of
the liver. The early detection of ALF may influence the prognosis of the
disease.
The present study demonstrated the presence of liver fibrosis
through the use of TE in around one-third of ACP patients. The levels
of liver enzymes and noninvasive fibrosis scores are not reliable
parameters with which to reveal liver fibrosis in ACP. The quantity of
consumed alcohol and the presence of DM are risk factors for the
development of liver fibrosis in ACP.
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